The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.
Sarcomas
account for less than 1.0% of all adult cancers. Though sarcomas represent a
heterogeneous group of over 50 different histological subtypes, the two major
subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000
patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every
year.
For
over 40 years, the mainstay of localized sarcoma treatment included surgical
resection followed by neoadjuvant or adjuvant radiation or
chemotherapy. However, even after complete surgical resection, about 50.0%
of patients with intermediate or high grade sarcoma develop metastatic disease.
The introduction of targeted therapy has revolutionized the treatment paradigm
for sarcoma. Targeted therapies and pipeline breakthroughs will continue to
play a pivotal role in the growth of the market throughout the forecast period.
Full Research Report On Sarcoma Drugs Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/sarcoma-drugs-market
Further key
findings from the report suggest:
- EU5 will remain the second
largest market with more than 30% share by 2023. The growth of the segment
can be attributed to the rising incidence of STS, uptake of targeted
therapies, and increasing R&D activities
- Eli Lilly’s Lartuvo has
displaced standard doxorubicin therapy as front-line STS treatment and is
anticipated to maintain its prominence in the market over the forecast
period
- Strong unmet needs within
the market present a key opportunity to develop breakthrough
first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma,
seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the
remaining in Phase I and Pre-clinical trials
- The potential role for use
of immuno-oncology agents in sarcomas is currently under evaluation in
Phase I/II clinical trials
- Companies with late-stage
pipeline products for sarcoma are likely to enter the market by 2019 and
would capture more than 10.0% of the sarcoma market share in 2023
- Drugs with novel targets in
early-phase development include Novartis’s Afinitor (mTOR inhibitor),
Tesaro’s Zejula (PARP inhibitor), Amgen’s Imlygic (gene therapy), and
Pfizer’s Crizotinib (ALK and MET tyrosine kinases inhibitor)
- The role of VEGF inhibitors
and mTOR inhibitors is under evaluation in multiple early phase trials.
However, no statistically significant data has been reported to date
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/sarcoma-drugs-market/request/rs1
Grand View Research has segmented
the global sarcoma drugs market based on treatment type and region:
Sarcoma Drugs
Treatment Class Outlook (Revenue, USD Million, 2017 - 2023)
- Chemotherapy
- Targeted Therapy
Sarcoma Drugs
Country Outlook (Revenue, USD Million, 2017 - 2023)
- The U.S.
- The U.K.
- Germany
- France
- Italy
- Spain
- Japan
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment